Welcome to our dedicated page for Merus news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus stock.
Merus N.V. (MRUS) is a clinical-stage biotechnology company pioneering bispecific antibody therapeutics for cancer treatment through its Biclonics® platform. This page provides investors and researchers with centralized access to official announcements, clinical trial updates, and strategic developments shaping the company's trajectory in immuno-oncology.
Find timely updates on Merus' investigational therapies, including progress across multiple cancer indications. Track key milestones such as regulatory feedback, partnership expansions with pharmaceutical collaborators, and financial performance updates. Our aggregation ensures efficient monitoring of material events without promotional bias.
Content spans clinical data disclosures, research collaborations with industry leaders like Incyte and Lilly, intellectual property developments, and financial reporting. Each update is categorized for quick scanning while maintaining technical accuracy required for biotech analysis.
Bookmark this page for streamlined access to Merus' evolving story in multispecific antibody development. Combine our news repository with SEC filings and scientific publications for comprehensive investment research approach.
Merus N.V. (Nasdaq: MRUS) reported its Q2 2021 financial results, with cash and equivalents rising to $352.8 million, expected to fund operations into H2 2024. Collaboration revenue surged to $12.4 million, primarily from Eli Lilly and Incyte. The company shared promising interim results from its Zeno program targeting NRG1 fusion cancers, showing 42% partial response in pancreatic cancer. Ongoing trials for MCLA-158 and MCLA-145 are set for updates in Q4 2021. However, R&D expenses increased, leading to a net loss of $27.4 million for the quarter.
Merus N.V. (Nasdaq: MRUS) announced the novel mechanism of action for its clinical-stage Biclonics® T-cell agonist, MCLA-145, which targets PD-L1 and CD137. Published in Nature Communications, the study reveals MCLA-145's ability to activate immune T cells in tumor microenvironments while blocking inhibitory signals. Currently, MCLA-145 is in a phase 1 multicenter dose escalation study for solid tumors, with Merus retaining U.S. commercialization rights, while Incyte holds rights outside the U.S.
On July 7, 2021, Merus N.V. (Nasdaq: MRUS) announced that CEO Bill Lundberg, M.D. will participate in the panel discussion titled Moving Beyond Monoclonals: The Potential of Multispecific Therapies at William Blair's Biotech Focus Conference 2021. The event is scheduled for July 14 at 11:20 a.m. ET. Investors can access the live webcast on the Company's website, with an archived presentation available for a limited time.
Merus specializes in developing innovative multispecific antibodies, known as Biclonics® and Triclonics®.
Merus has shared interim efficacy data from the phase 1/2 eNRGy trial for zenocutuzumab (Zeno) in patients with NRG1+ cancers, with 61 patients enrolled as of April 13, 2021. Notable findings reveal a 42% overall response rate in pancreatic cancer and a 29% rate across various NRG1+ tumor types. Zeno demonstrates a favorable safety profile, with most adverse events being mild or moderate. The company plans to discuss these results further in an investor call on June 6, 2021.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that its CEO, Bill Lundberg, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2 at 9:00 a.m. ET. The session will be accessible via a live webcast on the company's Investors page, with an archived version available afterward. Merus focuses on developing innovative multispecific antibodies, particularly its Biclonics® and Triclonics® products, which aim to advance cancer treatment.
Merus N.V. (MRUS) announced interim results from its phase 1/2 eNRGy trial investigating zenocutuzumab (Zeno) in patients with NRG1+ cancers. As of January 12, 2021, 51 patients were treated, with 33 evaluable for response, showing 27% overall response rate (ORR) and 40% ORR in pancreatic cancer. The safety profile remains favorable, with most adverse events mild or moderate. An oral presentation of updated interim analysis is set for ASCO on June 4, and an investor call is planned for June 6 to discuss results and provide program updates.
Merus N.V. (Nasdaq: MRUS) announced new collaborations in Israel, Italy, and Spain to enhance molecular screening for patients with cancers linked to neuregulin 1 (NRG1) fusions and promote the eNRGy clinical trial for its bispecific antibody, zenocutuzumab (Zeno). Progenetics, AISP, and Universidad de Navarra will educate patients and oncologists about these screenings. This initiative aims to improve patient treatment options and potentially recruit more patients for the eNRGy trial, which evaluates Zeno's safety and efficacy in treating NRG1+ cancers.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 18 at 8:00 a.m. ET. The presentation will be available via a live webcast on the company's Investors page, with an archived version accessible for a limited time afterward.
Merus specializes in developing innovative multispecific antibodies, known as Biclonics® and Triclonics®, aiming to provide advanced therapeutic options in cancer treatment.
Merus N.V. (Nasdaq: MRUS) announced its Q1 2021 financial results, showing a total revenue of $8.35 million, a significant increase from $6.30 million in Q1 2020. The operating loss was $21.79 million, up from $19.57 million year-over-year. Cash and equivalents rose to $374.4 million, bolstered by a follow-on offering and a $60 million collaboration with Lilly. Key highlights include the upcoming ASCO presentation on zenocutuzumab and the advancement of its clinical pipeline with MCLA-145 and MCLA-129 trials. Additionally, Cecile Geuijen was promoted to Chief Scientific Officer.
Merus N.V. (Nasdaq: MRUS) has commenced a phase 1/2 clinical trial for MCLA-129, a bispecific antibody targeting advanced non-small cell lung cancer (NSCLC) and other solid tumors. This trial aims to evaluate safety, tolerability, and clinical activity, focusing on determining the maximum tolerated dose. MCLA-129, developed in collaboration with Betta Pharmaceuticals, has shown promise in preclinical studies for treating EGFR-resistant NSCLC. This strategic initiative marks a significant advancement in Merus' oncology portfolio, aimed at addressing treatment resistance.
FAQ
What is the current stock price of Merus (MRUS)?
What is the market cap of Merus (MRUS)?
